Clover Health Investments Future Growth
Future criteria checks 0/6
Clover Health Investments's revenue is forecast to decline at 5.1% per annum while its annual earnings are expected to grow at 32% per year. EPS is expected to grow by 33.9% per annum. Return on equity is forecast to be -24.3% in 3 years.
Key information
32.0%
Earnings growth rate
33.9%
EPS growth rate
| Healthcare earnings growth | 16.3% |
| Revenue growth rate | -5.1% |
| Future return on equity | -24.3% |
| Analyst coverage | Low |
| Last updated | 20 Mar 2024 |
Recent future growth updates
Recent updates
Clover Health Investments, Corp.'s (NASDAQ:CLOV) 26% Dip In Price Shows Sentiment Is Matching Revenues
Apr 20
Clover Health Investments, Corp. (NASDAQ:CLOV) Analysts Are Reducing Their Forecasts For This Year
Mar 16Will Clover Health Investments (NASDAQ:CLOV) Spend Its Cash Wisely?
Mar 06Clover Health: Its Luck May Have Ran Out
Feb 26Here's Why We're Not Too Worried About Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
Nov 21We're Hopeful That Clover Health Investments (NASDAQ:CLOV) Will Use Its Cash Wisely
Jul 07Chamath Palihapitiya-linked Clover Health Investments trading near all-time low
Oct 14Chamath Palihapitiya cuts stake in Clover Health to under 5%
Oct 04Rethinking My Clover Health Position
Sep 12Clover Paid The Price Of Its Alleged Lies; Time To Move On
Aug 17Clover Health Investments to name president Andrew Toy as CEO
Aug 08Clover Health Is A Buy Ahead Of Earnings
Jul 29Clover Health to expand Medicare Advantage plans to 13 additional counties, exit 2
Jul 15Is Clover Health A Good Healthcare Sector Stock Pick?
Jun 30Clover Set To Report Earnings Tonight: Levels To Watch
May 09Analysts Are Betting On Clover Health Investments, Corp. (NASDAQ:CLOV) With A Big Upgrade This Week
Mar 04Good News From Clover Health
Feb 25Clover Health Is Now Undervalued, But Gains Not Guaranteed
Jan 24Clover Health: Roles Reversed As Institutions Buy The Dip And Retail Investors Bottle Out
Dec 03Why Clover Health Investments (NASDAQ:CLOV) has Time to Develop a Superior Product
Oct 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,404 | -86 | N/A | N/A | 2 |
| 12/31/2025 | 1,336 | -104 | N/A | N/A | 3 |
| 12/31/2024 | 1,275 | -115 | N/A | N/A | 3 |
| 12/31/2023 | 2,036 | -213 | -116 | -116 | N/A |
| 9/30/2023 | 2,440 | -226 | -101 | -96 | N/A |
| 6/30/2023 | 2,841 | -260 | 20 | 24 | N/A |
| 3/31/2023 | 3,195 | -336 | -72 | -68 | N/A |
| 12/31/2022 | 3,579 | -340 | -291 | -286 | N/A |
| 9/30/2022 | 3,041 | -443 | -76 | -75 | N/A |
| 6/30/2022 | 2,564 | -402 | -222 | -222 | N/A |
| 3/31/2022 | 2,075 | -615 | -247 | -246 | N/A |
| 12/31/2021 | 1,361 | -588 | -283 | -282 | N/A |
| 9/30/2021 | 1,158 | -527 | -263 | -262 | N/A |
| 6/30/2021 | 922 | -487 | -252 | -252 | N/A |
| 3/31/2021 | 721 | -160 | -175 | -174 | N/A |
| 12/31/2020 | 690 | -136 | -119 | -118 | N/A |
| 9/30/2020 | 624 | -89 | -126 | -126 | N/A |
| 6/30/2020 | 572 | -145 | -116 | -116 | N/A |
| 3/31/2020 | 507 | -272 | -163 | -163 | N/A |
| 12/31/2019 | 455 | -364 | -160 | -160 | N/A |
| 12/31/2018 | 281 | -202 | -155 | -153 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLOV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLOV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLOV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLOV's revenue is expected to decline over the next 3 years (-5.1% per year).
High Growth Revenue: CLOV's revenue is forecast to decline over the next 3 years (-5.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLOV is forecast to be unprofitable in 3 years.